Table 3. Studies using ST-2 for cardiovascular risk stratification.

Studies	n	Endpoint	Thresholds	Hazard ratio
ACS[138]	373	All-cause mortality	5–538 pg/mL,539–3618 pg/mL	2.1,2.2
NSTE-ACS[145]	4432	Cardiovascular death, HF, MI, recurrent ischemia	< 35 ng/mL, ≥ 35 ng/mL	2.08,1.19
MERLIN-TIMI 36 Trial[143]	6560	Cardiovascular death, HF	> 35 µg/L	1.9
STEMI[137]	677	All-cause mortality at 30 days and 1 year	Median	9.34,3.15
LURIC study[141]	1345	All-cause mortality	> 24.6 ng/mL	1.39
AHF[146]	107	All-cause mortality	> 65 ng/mL	1.09
AHF[147]	5306	All-cause mortality	Median	10.3
CHF[148]	876	All-cause and cardiovascular mortality	Quartile (< 30.9 ng/mL, 31−38.3 ng/mL, 38.4−51.1 ng/mL, > 51.1 ng/mL)	1.45,1.55

ACS: acute coronary syndrome; AHF: acute heart failure; CHF: chronic heart failure; HF: heart failure; NSTE-ACS: non-ST-segment-elevation-acute coronary syndrome; STEMI: ST-segment–elevation myocardial infarction.